Cambridge Heart Announces New Software Release

New user interface and patient database, and EMR Compatibility

TEWKSBURY, Mass.--(BUSINESS WIRE)-- Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced the release of its redesigned Microvolt T-Wave Alternans (MTWA) software for its HearTwave II and CH2000 platforms. The new software release includes a significantly updated user interface and patient database, and supports industry integration standards into electronic medical record (“EMR”) environments. The new software will help physicians streamline the practice workflow and allow them to access a patient's test results electronically through their EMR systems. The new software supports major industry reporting standards including HL7 and DICOM, optimizing connectivity to leading electronic medical records systems in the market. The software will be available to all existing and new customers and will begin shipping in May.

Ali Haghighi-Mood, CEO of Cambridge Heart, said, “This new software will enable our customers, particularly multi-physician practices and hospitals, to realize an increase in the usability of our products, and supports their goals of a transition into EMR environments by providing compatibility with industry standards. The new user interface and database were developed in response to our customers’ requests to enable more efficient use of our products when performing MTWA testing.”

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans™ measurement technologies, including the patented Analytic Spectral Method® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.

Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.


At Cambridge Heart:
Vincenzo LiCausi, 978-654-7600 x 6645
Chief Financial Officer
[email protected]
KOGS Communication
Edna Kaplan, 781-639-1910
[email protected]
Investor Relations:
Wolfe Axelrod Weinberger Associates, LLC
Stephen D. Axelrod, CFA
Diana Bittner (general inquiries)
[email protected]
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Hardware  Software  Health  Biotechnology  Cardiology  Clinical Trials  Hospitals  Medical Devices